BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Discovery By Research Group At Boston Biomedical Research Institute Opens Doors To New Treatments For The Most Lethal Cancers


2/28/2006 11:46:47 AM

WATERTOWN, Mass., Feb. 27 /PRNewswire/ -- Cancer Research, a top-tier journal that publishes biologically significant findings with relevance to cancer, recently published the findings of Dr. Charles P. Emerson, Jr., a Senior Scientist and Director of the not-for-profit Boston Biomedical Research Institute and Dr. Natalia Riobo, a postdoctoral fellow at the University of Pennsylvania School of Medicine. The discovery holds promise for identification of new drug targets to treat a group of the most lethal cancers known as Hedgehog cancers.

Drs. Emerson and Riobo's research focuses on understanding a type of cell communication know as Hedgehog signaling. Hedgehog signaling has an essential role in the control of stem cell growth and in the promotion of tumor growth. Excessive activation of the Hedgehog signaling pathway has been observed to be responsible for tumor growth in the most lethal of human cancers, including pancreatic, lung, skin, muscle and digestive tract cancer -- all of which remain largely untreatable. These researchers now show that two kinases, known as PKC-delta and MEK-1, cooperate with Hedgehog signaling to activate GLI transcription factors to regulate key genes that control stem cell and tumor growth.

"Understanding the key components of the Hedgehog signaling pathway, and how mutations in this pathway can lead to the growth of cancer cells, highlights the power of basic science and disease model research to reveal new therapeutic approaches for human disease, which is a hallmark of BBRI research," says BBRI's Director Dr. Charles Emerson. "Our preliminary findings offer tremendous promise for development of preventative and curative treatments for these devastating cancers." The work is being supported by a grant from the National Cancer Institute.

Boston Biomedical Research Institute is a not-for-profit institution dedicated to the understanding, treatment and prevention of specific human diseases including cancer, cardiovascular disease, Alzheimer's disease, muscular dystrophy, diabetes and conditions such as obesity and reproductive health problems. For more information visit http://www.bbri.org.

Boston Biomedical Research Institute

CONTACT: Terence McGowan, of Boston Biomedical Research Institute,+1-617-658-7707, mcgowan@bbri.org



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES